Receptagen to Develop 'Growth Blocker' Monoclonal Antibody

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 4
Volume 4
Issue 4

SEATTLE--Receptagen Ltd. has begun formal clinical development of its first "growth blocker" drug, based on promising laboratory studies. The agent, a monoclonal antibody that blocks the B12 carrier protein trans-cobalamin II, triggered apoptosis in cancer cells by depleting vitamin B12, an essential enzyme co-factor for cell proliferation, said Receptagen president A. Charles Morgan Jr., PhD.

SEATTLE--Receptagen Ltd. has begun formal clinical developmentof its first "growth blocker" drug, based on promisinglaboratory studies. The agent, a monoclonal antibody that blocksthe B12 carrier protein trans-cobalamin II, triggered apoptosisin cancer cells by depleting vitamin B12, an essential enzymeco-factor for cell proliferation, said Receptagen president A.Charles Morgan Jr., PhD.

Articles in this issue
First Results of Avicidin Trials
Chemo Patients Often Develop Menstrual Irregularities
Growth Factor Receptor Blockade Moving From Laboratory to Clinic
Controlled-Release AZT Gets FDA Go-Ahead for New Drug Investigation
Vinorelbine Plus Chemo Promising in Advanced Disease
Bone Substudy a Part of Tamoxifen Prevention Trial
Ultrasound Breast Screens Useful in Selected Women
New Roles Forecast for Endocrine Therapy
Antisense Drug Against BCL-2 Effective in Animal Cancer Models
Anticancer Drugs From Zeneca in Regulatory Phase of Development
Osteosarcoma Chemo Regimens Debated
Primary Chemotherapy Allows Breast-Conserving Surgery in French Study
Cancer Care, Inc. Sponsors Make-Up Clinics for Chemo Patients
$2 Billion Budget for NCI Proposed
Risk of Gyn Cancer Increases After Diagnosis of Breast Cancer

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
“Developments that take high-dimensional data and come up with interpretable insights…are going to play an increasing role,” says Smita Krishnaswamy, PhD.
4 experts in this video
5 experts are featured in this series
5 experts are featured in this series
4 experts in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
1 expert in this video
Related Content
Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Real-World Data Show Activity With Ivosidenib in IDH1+ Cholangiocarcinoma

Kyle Doherty
July 11th 2025
Article

Data from the phase 3b ProvIDHe trial show "reassuringly good" PFS and OS outcomes with ivosidenib in a real-world cohort.

Best Practices for the Medical Oncology Boards

Best Practices for the Medical Oncology Boards

Eric Singhi, MD;Nicholas James Hornstein, MD, PhD;Marc Braunstein, MD, PhD;Nerea M. Lopetegui-Lia, MD;MinhTri Nguyen, MD
July 7th 2025
Podcast

A group of clinicians gives study advice on how to best prepare for the medical oncology board examinations.

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Enzalutamide Prolongs Survival in nmHSPC With Biochemical Recurrence

Tim Cortese
July 11th 2025
Article

More detailed overall survival results from the phase 3 EMBARK trial for patients with nmHSPC will be shared at an upcoming medical conference.

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Unveiling Advances in GU Cancers: Insights from Oncology Decoded

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;John Burke, MD;Dhaval R. Shah, MBBS
July 3rd 2025
Podcast

Dive into the latest in genitourinary oncology with "Oncology Decoded," featuring discussions on KEYNOTE-564 with RCC.

For the First Time, A Nilotinib Without Fasting Restrictions

For the First Time, A Nilotinib Without Fasting Restrictions

July 11th 2025
Article
Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.

Tarlatamab Shows Promising Real-World Activity in Extensive-Stage SCLC

Russ Conroy
July 11th 2025
Article

Treatment with tarlatamab demonstrated intracranial responses in a real-world cohort of patients with extensive-stage small cell lung cancer.